Literature DB >> 21809486

Oxidized low-density lipoprotein is associated with viral load and disease activity in patients with chronic hepatitis C.

Manouchehr Nakhjavani1, Arshideh Mashayekh, Omid Khalilzadeh, Firouzeh Asgarani, Afsaneh Morteza, Mohammad Omidi, Hossein Froutan.   

Abstract

BACKGROUND: The mechanisms of liver injury in chronic hepatitis C virus (HCV) infection are poorly understood. Recent evidence suggests that oxidative stress and lipid-peroxidation play a major role. The purpose of this study was to determine the serum level of oxidized low-density lipoprotein (ox-LDL), and evaluate its association with different clinically valuable parameters of liver disease in patients with chronic hepatitis C.
METHODS: Forty-five untreated chronic hepatitis C patients and 45 healthy adult volunteers, matched for age, sex and BMI, were enrolled. Blood samples were collected after 12 h of fasting, and serum bilirubin, albumin, liver aminotransferases, lipid profile, prothrombin time and ox-LDL were measured. Viral load of HCV was determined in patients. Liver biopsy was performed in patients and the stage of fibrosis and grade of necroinflammatory activity were determined. Healthy controls did not undergo liver biopsy.
RESULTS: Ox-LDL was significantly higher in HCV patients (42.54 ± 3.82 vs. 30.98 ± 1.66 μ/l, P < 0.01). Ox-LDL was significantly correlated to viral load (r = 0.457, P < 0.01), and grade of inflammation (r = 0.293, P < 0.05) in HCV patients. Ox-LDL was significantly higher in cirrhotic vs. noncirrhotic patients. No significant association was found between ox-LDL and Child-Pugh classification, serum albumin, liver enzymes, or prothrombin time.
CONCLUSION: This study provided new data from an in vivo setting which suggests the contribution of ox-LDL to HCV pathogenesis. Our results encourage further clinical studies to evaluate the potential diagnostic and therapeutic implications of ox-LDL in HCV patients.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21809486     DOI: 10.1016/j.clinre.2010.11.001

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  5 in total

1.  Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats.

Authors:  Hui-Chun Huang; Shao-Jung Hsu; Ching-Chih Chang; Chiao-Lin Chuang; Ming-Chih Hou; Fa-Yauh Lee
Journal:  Int J Mol Sci       Date:  2022-07-02       Impact factor: 6.208

2.  Investigation of the factors associated with circulating soluble CD36 levels in patients with HCV-related chronic liver disease.

Authors:  Takashi Himoto; Joji Tani; Hisaaki Miyoshi; Asahiro Morishita; Hirohito Yoneyama; Kazutaka Kurokohchi; Michio Inukai; Hisashi Masugata; Fuminori Goda; Shoichi Senda; Reiji Haba; Masaki Ueno; Genji Yamaoka; Tsutomu Masaki
Journal:  Diabetol Metab Syndr       Date:  2013-09-09       Impact factor: 3.320

3.  Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection.

Authors:  Philipp Solbach; Sandra Westhaus; Maximilian Deest; Eva Herrmann; Thomas Berg; Michael P Manns; Sandra Ciesek; Christoph Sarrazin; Thomas von Hahn
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-03-14

4.  Interactions between Hepatitis C Virus and the Human Apolipoprotein H Acute Phase Protein: A Tool for a Sensitive Detection of the Virus.

Authors:  Ilias Stefas; Sylvia Tigrett; Grégor Dubois; Marco Kaiser; Estelle Lucarz; Delphine Gobby; Dorothy Bray; Heinz Ellerbrok; Jean Pierre Zarski; Francisco Veas
Journal:  PLoS One       Date:  2015-10-26       Impact factor: 3.240

Review 5.  Mitochondrial dysfunctions and altered metals homeostasis: new weapons to counteract HCV-related oxidative stress.

Authors:  Mario Arciello; Manuele Gori; Clara Balsano
Journal:  Oxid Med Cell Longev       Date:  2013-11-24       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.